Abstract
Over the years Renal Transplant has become increasingly successful and fairly routine in terms of availability to prospective patients. More effective and better tolerated medications have led to decreased adverse immunologic events after transplant leading to improved graft survival. Moreover, since the last few years renal transplant is being offered to a wider range of patients with variety of comorbidities, thus making the surveillance of long term complications of immunosuppression (IS) medications critical for both graft and patient survival. As the use of newer and more potent medications becomes more wide spread, their adverse effects, interactions amongst themselves as well as with other medications, are necessary to recognize and follow closely specially in patients with other comorbidities. Although infections resulting from IS are common; other noninfectious complications cause significant problems in a transplant patient. Post-transplant, several preexisting risk factors like hypertension (HTN), dyslipidemia and hyperglycemia usually get exacerbated resulting in accelerated atherosclerosis causing cardiovascular disease which is the most common cause of death in transplant patients. Some IS medications have been implicated as a cause for certain malignancies and their close surveillance and timely intervention is an important aspect of care for these patients. Therefore an understanding of these medications and their adverse effects is of paramount importance for the successful medical management of these patients. In this manuscript we review the transplant IS and systematically outline their various noninfectious adverse effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.